DOCSLIB.ORG

Health Seeking Behaviour and Cost of Fever Treatment to Households in a Malaria Endemic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Health Seeking Behaviour and Cost of Fever Treatment to Households in a Malaria Endemic bioRxiv preprint doi: https://doi.org/10.1101/486183; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Health seeking behaviour and cost of fever treatment to households in a malaria endemic 2 setting of northern Ghana: A cross sectional study 3 4 Maxwell Ayindenaba Dalaba1*, Patricia Akweongo2, Philip Baba Adongo2, Philip Ayizem 5 Dalinjong1, Samuel Chatio1, and Abraham Oduro1 6 7 8 1 Navrongo Health Research Centre, P.O Box 114, Navrongo, Ghana 9 2 University of Ghana, School of Public Health, Accra, Ghana 10 11 12 13 14 15 16 Corresponding Author 17 Maxwell Ayindenaba Dalaba, Navrongo Health Research Centre, P.O Box 114, Navrongo, 18 Ghana 19 Email: [email protected] 20 21 22 23 1 bioRxiv preprint doi: https://doi.org/10.1101/486183; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 24 Abstract 25 Background: This study examined the health seeking behaviours and cost of treatment of malaria 26 to households in the Kassena-Nankana district of Ghana. 27 Methods: A cross-sectional household survey was conducted between July and September 2015. 28 Individuals who had an episode of fever or malaria in the past two weeks identified during routine 29 Health and Demographic Surveillance System data collection were selected for the study. Socio- 30 demographic characteristics, treatment seeking behaviours and cost of treatment of malaria were 31 obtained from the patient perspective. 32 Results: Out of the 1,845 households visited, 21.3% (393/1,845) reported to have had an episode 33 of fever or malaria in the past two weeks. Of the 393 people with malaria, 66.9% (263/393) 34 reported taking an antimalarial. About 53.6% (141/263) of the antimalarials were obtained from 35 formal healthy facilities. About 36.1% (95/263) reported to have taken Dihydroartemisinin- 36 piperaquine, 35.4 % (93/263) took Artesunate–Amodiaquine and 21.7% (57/263) took 37 Artemether-Lumefantrine. Only 49.6%% (195/393) of the study participants had their blood 38 sample taken for illness (microscopic or Rapid Diagnostic Test). Only 23.6% (62/263) took 39 antimalarial within 24 hours of the onset of illness. The overall average costs (direct and indirect 40 cost) incurred by households per malaria treatment was GH¢27.82/US$7.32 (range: GH¢0.2/ 41 US$0.05 - GH¢200/ US$52.63). The average cost incurred in the treatment of malaria by those 42 who were enrolled into the National Health Insurance Scheme (NHIS) was GH¢24.75/US$6.51 43 and those not enrolled was GH¢43.95/US$11.57. 44 Conclusions: Prompt treatment such as treatment within 24 hours of onset of malaria was low. 45 The average costs to households per malaria treatment was GH¢27.82/US$7.32 and the preferred 2 bioRxiv preprint doi: https://doi.org/10.1101/486183; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 46 antimalarial was Dihydroartemisinin-piperaquine. There was a positive effect of NHIS enrolment 47 on cost of treatment as the insured incurred less cost (US$5 less) in treatment than the uninsured. 48 Keywords: Malaria, fever, treatment-seeking behaviour, cost, Ghana. 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 3 bioRxiv preprint doi: https://doi.org/10.1101/486183; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 69 Introduction 70 According to the WHO report, there are an estimated 198 million malaria cases and 584 000 71 malaria deaths worldwide in 2013. The burden of malaria is more severe in sub-Saharan Africa 72 where about 90% of all malaria deaths occur [1]. It is a major cause of poverty and slows economic 73 growth by up to 1·3% per year in endemic countries[2]. 74 Malaria is a significant public health problem in Ghana where it accounts for about 33% of all 75 outpatient attendances and 49% of under five years admissions[3]. Malaria is a preventable, 76 diagnosable and treatable illness. The main methods for the prevention of malaria include Long- 77 Lasting Insecticidal Nets (LLINs), Indoor Residual Spraying (IRS), Intermittent Preventive 78 Treatment for pregnant women (IPTp) and vector control methods such as larviciding [1,4]. The 79 WHO has recommended that all persons from endemic areas with suspected malaria should be 80 examined for evidence of infections with malaria parasites by Rapid Diagnostic Test (RDT) or 81 microscopy. In addition, WHO recommended that uncomplicated malaria should be treated with 82 antimalarial such as Artemisinin-based combination therapies (ACTs), particularly in areas where 83 malaria is endemic and persons should have access to ACTs within 24 hours of onset of malaria 84 [1].The recommended ACT combinations are artemether-lumefantrine (AL), artesunate- 85 amodiaquine (AS+AQ), artesunate-mefloquine (AS+MQ), dihydroartemisinin-piperaquine (DP), 86 and artesunate-sulfadoxine-pyrimethamine (AS+SP). The choice of ACT in a country or region is 87 based on the level of resistance of the partner medicine in the combination [5,6]. 88 Following WHO recommendation, in 2004 Ghana changed her antimalarial drug policy choosing 89 Artesunate-Amodiaquine combination as the first line drug for the treatment of uncomplicated 90 malaria to replace chloroquine. However, the implementation process was confronted with some 91 challenges which relates to adverse drug reactions, safety concerns and absence of other treatment 4 bioRxiv preprint doi: https://doi.org/10.1101/486183; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 92 options. It therefore became necessary to review the new policy to address all recognized concerns. 93 A task force reviewed the existing policy and selected additional ACT drugs and dosage forms to 94 accommodate for those who could not bear the Artesunate- Amodiaquine combination. Two 95 additional first line ACTs namely; Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine 96 were selected thus making Ghana to have three official concurrent first line antimalarial treatments 97 [7]. 98 To date, however, the reaction of the health system to multiple alternative first line malaria therapy 99 has not been comprehensively studied. Little is known about access to effective and prompt 100 treatment and preferences for antimalarial drugs for treatment of fever/malaria as well as cost of 101 malaria treatment in the face of multiple first line treatment policy. This study therefore examined 102 the health seeking behaviours as well cost of treatment of malaria to households in the Kassena- 103 Nankana district of Ghana in the face of multiple first line antimalarial drugs. 104 105 Methods 106 Study area 107 The study was carried out in the Kassena-Nankana East and West Districts of the Upper East 108 Region of Ghana. The Kassena-Nankana East is home to the Navrongo Health Research Centre 109 (NHRC) and staff of the Centre conducted the study. The NHRC operates Health and Demographic 110 Surveillance System (HDSS) and has a data base of all individuals and households in the Kassena- 111 Nankana East and West Districts. For the purpose of research, the NHRC refers to the two districts 112 by their former name - the Kassena-Nankana District (KND). 5 bioRxiv preprint doi: https://doi.org/10.1101/486183; this version posted December 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 113 The KND covers an area of about 1,674 square kilometres of land [8]. The area is characterized 114 by a short rainy season and a prolonged dry season from October to March. The mean annual 115 rainfall is about 850mm, with the heaviest usually occurring in August. The total population 116 currently under surveillance is about 152 000 residing in about 32,000 households [8]. Malaria 117 transmission in the KND occurs all year round but there is a distinct seasonal pattern with the peak 118 of transmission coinciding with the period of the major rains (August) and the dry season seeing 119 very low rates of malaria infection[9]. 120 The districts have one district referral hospital located in Navrongo town and 8 health centres 121 strategically located across the district which provide secondary curative and preventive health 122 care. There are 28 Community Based Health Planning and Services (CHPS) compounds/clinics 123 located in various communities and providing primary health care treatment for minor ailments 124 and also carrying out childhood immunizations and antenatal services.
Load more

Recommended publications
  • Psychiatric Side Effects of Mefloquine: Applications to Forensic Psychiatry
    REGULAR ARTICLE Psychiatric Side Effects of Mefloquine: Applications to Forensic Psychiatry Elspeth Cameron Ritchie, MD, MPH, Jerald Block, MD, and Remington Lee Nevin, MD, MPH Mefloquine (previously marketed in the United States as Lariam®) is an antimalarial medication with potent psychotropic potential. Severe psychiatric side effects due to mefloquine intoxication are well documented, including anxiety, panic attacks, paranoia, persecutory delusions, dissociative psychosis, and anterograde amnesia. Exposure to the drug has been associated with acts of violence and suicide. In this article, we discuss the history of mefloquine use and describe plausible mechanisms of its psychotropic action. Mefloquine intoxication has not yet been successfully advanced in legal proceedings as a defense or as a mitigating factor, but it appears likely that it eventually will be. Considerations for the application of claims of mefloquine intoxication in forensic settings are discussed. J Am Acad Psychiatry Law 41:224–35, 2013 Mefloquine is a 4-quinolinemethanol antimalarial The company pursued regulatory approval and mar- first synthesized in the early 1970s1 by researchers keted the drug to civilian travelers in the United affiliated with the United States military’s Walter States under the trade name Lariam® after its initial Reed Army Institute of Research (WRAIR).2 The Food and Drug Administration (FDA) licensure in drug’s development was the culmination of a 10-year 1989.5 Owing to its efficacy, presumed safety, and drug discovery effort, during which time more than convenient dose schedule that facilitated prophylac- 300,000 compounds were screened for their antima- tic use, mefloquine was soon identified as the drug of 2 larial properties.
    [Show full text]
  • How to Protect Yourself Against Malaria 1 Fig
    From our Whitepaper Files: How to > See companion document Protect Yourself Against Malaria World Malaria Risk Chart 2015 Edition Canada 67 Mowat Avenue, Suite 036 Toronto, Ontario M6K 3E3 (416) 652-0137 USA 1623 Military Road, #279 Niagara Falls, New York 14304-1745 (716) 754-4883 New Zealand 206 Papanui Road Christchurch 5 www.iamat.org | [email protected] | Twitter @IAMAT_Travel | Facebook IAMATHealth THE ENEMY area. Of the 460 Anopheles species, approximately 100 can transmit malaria Sunset — the hunt for human blood begins. parasites. From dusk to dawn the female Anopheles, Mosquitoes prey on a variety of hosts — the malaria-carrying mosquito searches for a host humans, monkeys, lizards, birds — carrying to supply her with blood. Blood is an absolute different species of malaria parasites which in necessity for her because it provides the protein turn infect only specific hosts. Of the approxi- needed for the development of her eggs which mately 50 different species of malaria parasites she later deposits in her breeding place. sharing the genetic name Plasmodium, only She has a tiny, elegant body, measuring 5 infect humans: Plasmodium falciparum, from 8 mm to 1 cm. She has dark spots on the killer; Plasmodium vivax; Plasmodium ovale, her wings, three pairs of long, slender legs and Plasmodium malariae and Plasmodium knowlesi. a prominent tubular proboscis with which The latter, a malaria parasite of Old World she draws blood. monkeys, has been identified to infect humans Fig. 1 Female Anopheles mosquito. The Anopheles enters your room at night. in Southeast Asia. In the past this parasite has Image source: World Health Organization You may recognize her by the way she rests been misdiagnosed as Plasmodium malariae.
    [Show full text]
  • Drug Resistance in Malaria Eugene Mark Department of Biochemistry University of Ghana
    http://www.inosr.net/inosr-scientific-research/ INOSR Scientific Research 4(1): 1-12, 2018. Eugene ©INOSR PUBLICATIONS International Network Organization for Scientific Research ISSN: 2705-1706 Drug Resistance in Malaria Eugene Mark Department of Biochemistry University of Ghana ABSTRACT Drug resistant malaria is primarily caused Established and strong drug pressure by Plasmodium falciparum, a species combined with low antiparasitic immunity highly prevalent in tropical. It causes probably explains the multidrug-resistance severe fever or anaemia that leads to more encountered in the forests of South-east than a million deaths each year. The Asia and South America. In Africa, emergence of chloroquine resistance has frequent genetic recombination in been associated with a dramatic increase Plasmodium originate from a high level of in malaria mortality among inhabitants of malaria transmission, and falciparum some endemic regions. The mechanisms of chloroquine-resistant prevalence seems to resistance for amino-alcohols (quinine, stabilize at the same level as chloroquine- mefloquine and halofantrine) are still sensitive malaria. Nevertheless, resistance unclear. Epidemiological studies have levels may differ according to place and established that the frequency of time. In vivo and in vitro tests do not chloroquine resistant mutants varies provide an adequate accurate map of among isolated parasite populations, while resistance. Biochemical tools at a low cost resistance to antifolates is highly prevalent are urgently needed for prospective in most malarial endemic countries. monitoring of resistance. Keywords: Drug, Resistance, Malaria. INTRODUCTION Malaria is a mosquito-borne infectious reproduce [3]. Five species of Plasmodium disease that affects humans and other can infect and be spread by humans.
    [Show full text]
  • Hydroxychloroquine: a Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/02/08/jpet.117.245639.DC1 1521-0103/365/3/447–459$35.00 https://doi.org/10.1124/jpet.117.245639 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 365:447–459, June 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation s Keagan P. Collins, Kristen M. Jackson, and Daniel L. Gustafson School of Biomedical Engineering (K.P.C., K.M.J., D.L.G.) and Department of Clinical Sciences (D.L.G.), Colorado State University, Fort Collins, Colorado; and University of Colorado Cancer Center, Aurora, Colorado (D.L.G.) Received October 10, 2017; accepted February 6, 2018 ABSTRACT Downloaded from Hydroxychloroquine (HCQ) is a lysosomotropic autophagy in- adapted to simulate human HCQ exposure in whole blood and hibitor being used in over 50 clinical trials either alone or in urine through allometric scaling and species-specific parameter combination with chemotherapy. Pharmacokinetic (PK) and modification. The human model accurately simulated average pharmacodynamic (PD) studies with HCQ have shown that drug steady-state concentrations (Css) of those observed in five exposure in the blood does not correlate with autophagy different HCQ combination clinical trials across seven different inhibition in either peripheral blood mononuclear cells or tumor doses, which was then expanded by comparison of the Css tissue. To better explain this PK/PD disconnect, a PBPK was distribution in a virtual human population at this range of doses.
    [Show full text]
  • PHARMACOLOGY of NEWER ANTIMALARIAL DRUGS: REVIEW ARTICLE Bhuvaneshwari1, Souri S
    REVIEW ARTICLE PHARMACOLOGY OF NEWER ANTIMALARIAL DRUGS: REVIEW ARTICLE Bhuvaneshwari1, Souri S. Kondaveti2 HOW TO CITE THIS ARTICLE: Bhuvaneshwari, Souri S. Kondaveti. ‖Pharmacology of Newer Antimalarial Drugs: Review Article‖. Journal of Evidence based Medicine and Healthcare; Volume 2, Issue 4, January 26, 2015; Page: 431-439. ABSTRACT: Malaria is currently is a major health problem, which has been attributed to wide spread resistance of the anopheles mosquito to the economical insecticides and increasing prevalence of drug resistance to plasmodium falciparum. Newer drugs are needed as there is a continual threat of emergence of resistance to both artemisins and the partner medicines. Newer artemisinin compounds like Artemisone, Artemisnic acid, Sodium artelinate, Arteflene, Synthetic peroxides like arterolane which is a synthetic trioxolane cognener of artemisins, OZ439 a second generation synthetic peroxide are under studies. Newer artemisinin combinations include Arterolane(150mg) + Piperaquine (750mg), DHA (120mg) + Piperaquine(960mg) (1:8), Artesunate + Pyronardine (1:3), Artesunate + Chlorproguanil + Dapsone, Artemisinin (125mg) + Napthoquine (50mg) single dose and Artesunate + Ferroquine.Newer drugs under development including Transmission blocking compounds like Bulaquine, Etaquine, Tafenoquine, which are primaquine congeners, Spiroindalone, Trioxaquine DU 1302, Epoxamicin, Quinolone 3 Di aryl ether. Newer drugs targeting blood & liver stages which include Ferroquine, Albitiazolium – (SAR – 97276). Older drugs with new use in malaria like beta blockers, calcium channel blockers, protease inhibitors, Dihydroorotate dehydrogenase inhibitors, methotrexate, Sevuparin sodium, auranofin, are under preclinical studies which also target blood and liver stages. Antibiotics like Fosmidomycin and Azithromycin in combination with Artesunate, Chloroquine, Clindamycin are also undergoing trials for treatment of malaria. Vaccines - RTS, S– the most effective malarial vaccine tested to date.
    [Show full text]
  • Malaria Surveillance — United States, 2017
    Morbidity and Mortality Weekly Report Surveillance Summaries / Vol. 70 / No. 2 March 19, 2021 Malaria Surveillance — United States, 2017 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Surveillance Summaries CONTENTS Introduction ............................................................................................................2 Methods ....................................................................................................................4 Results .......................................................................................................................6 Discussion ............................................................................................................. 26 References ............................................................................................................. 32 The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027. Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR Surveill Summ 2021;70(No. SS-#):[inclusive page numbers]. Centers for Disease Control and Prevention Rochelle P. Walensky, MD, MPH, Director Anne Schuchat, MD, Principal Deputy Director Daniel B. Jernigan, MD, MPH, Acting Deputy Director for Public Health Science and Surveillance Rebecca Bunnell, PhD, MEd, Director, Office of Science Jennifer Layden,
    [Show full text]
  • Springer MRW: [AU:0, IDX:0]
    P Pharmacology of Antimalarial studies were performed by German scientists just Drugs, Current Anti-malarials before World War II. However, the drug was reported to be too toxic for human use and not Kesara Na-Bangchang1 and Juntra Karbwang2 introduced for general use at that time. By late 1Chulabhorn International College of Medicine, 1944, in the intensive search for an effective anti- Thammasat University, Pathumtanee, Thailand malarial drug during World War II, US workers 2Clinical Product Development, Institute of synthesized 25 different 4-aminoquinoline deriv- Tropical Medicine, Nagasaki, Japan atives, with the objective of discovering more effective and less toxic suppressive agents than quinacrine. Of these compounds, chloroquine Currently available antimalarial drugs can be clas- proved the most promising and later underwent sified into four broad categories according to their extensive clinical studies. Since then, chloroquine chemical structures and modes of action. had been used as the drug of choice for treatment of human malaria all over the world until the 1. Arylamino alcohol compounds: quinine, quin- advent of chloroquine resistance in Plasmodium idine, chloroquine, amodiaquine, mefloquine, falciparum in the early 1960s. Clinical treatment halofantrine, piperaquine, and lumefantrine failures of P. falciparum were first noted in 2. 8-Aminoquinoline: primaquine and Thailand almost at the same time as in South tafenoquine America. Chloroquine-resistant P. falciparum 3. Antifolate compounds: sulfadoxine, pyrimeth- has since then spread relentlessly to virtually all amine, proguanil, chlorproguanil, and areas of the world except Central America, North trimethoprim Africa, and parts of Western Asia. 4. Artemisinin compounds: artemisinin, artesunate, artemether, b-arteether, and dihydroartemisinin Chemistry and Physical Properties 5.
    [Show full text]
  • Guidelines on Malaria Chemoprophylaxis for Travellers from Hong Kong
    Scientific Committee on Vector-borne Diseases Guidelines on Malaria Chemoprophylaxis for Travellers from Hong Kong Purpose This paper details the approaches for clinicians who may need to provide advice or prescriptions against malaria to travellers from Hong Kong. Approaches to Malaria Prevention for Travellers 2. The majority of infections and deaths due to malaria are preventable. The keys to prevention lie in the following four principles1,2: (a) awareness of the risk of malaria among travellers; (b) preventing mosquito bites; (c) the proper use of chemoprophylaxis and good drug compliance; and (d) a high index of suspicion for breakthrough infection. Awareness of the Risk of Malaria 3. Malaria is a vector-borne disease transmitted by several species of female Anopheline mosquitoes. It is a disease caused by protozoan parasites belonging to the genus Plasmodium, comprising Plasmodium vivax, Plasmodium falciparum, Plasmodium ovale, and Plasmodium malariae. 4. Clinically, malarial infection presents as an acute febrile illness with incubation period ranging from 7 days to up to 1 year or even longer. Patients may present with fever, chills, headache, muscular pain and weakness, vomiting, cough, diarrhea, and abdominal pain. Severe malaria is usually caused by P. falciparum and may be manifested as renal failure, generalized convulsion, circulatory collapse, and coma. Falciparum malaria may be fatal if treatment is delayed beyond 24 hours. Plasmodium vivax and Plasmodium ovale have dormant liver stages and may cause relapse months or years later. Plasmodium malariae has been known to persist in the blood of some persons for several decades. 5. Currently there is no vaccine against malaria.
    [Show full text]
  • A Comprehensive Review of Malaria with an Emphasis on Plasmodium Resistance
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by The University of Mississippi A COMPREHENSIVE REVIEW OF MALARIA WITH AN EMPHASIS ON PLASMODIUM RESISTANCE Lindsay Thomas A thesis submitted to the faculty of The University of Mississippi in partial fulfillment of the Sally McDonnell Barksdale Honors College. Oxford May 2014 Approved by: Advisor: Dr. Michael Warren Reader: Dr. Matthew Strum Reader: Dr. Donna West-Strum ii © 2014 Lindsay O’Neal Thomas ALL RIGHTS RESERVED iii ABSTRACT Malaria is a disease that is caused by the Plasmodium genus. It is endemic in tropical areas. There are multiple drugs used for prophylaxis and treatment. However, the parasites have developed resistance towards most antimalarial pharmaceuticals. The pharmaceutical industry is generating new antimalarial pharmaceuticals, but the rate of new Plasmodium resistance is much faster. iv TABLE OF CONTENTS List of Figures…………………………………………………………...v List of Abbreviations…………………………………………………....vi Introductions…………………………………………………………….1 Chapter I: Background…………………………………………………..4 Chapter II: Life cycle of Malaria ……………………………………......7 Chapter III: The Disease………………………………………………..11 Chapter IV: Blood Schizonticides……………………………………....15 Chapter V: Tissue Schizonticides……………………………………....25 Chapter VI: Hypnozoitocides…………………………………………...31 Chapter VII: Artemisinin……………………………………………….34 Chapter VIII: Future Resistance………………………………………...36 Conclusion………………………………………………………………38 Bibliography…………………………………………………………….40 v LIST OF FIGURES FIGURE 1:
    [Show full text]
  • Malaria Surveillance — United States, 2015
    Morbidity and Mortality Weekly Report Surveillance Summaries / Vol. 67 / No. 7 May 4, 2018 Malaria Surveillance — United States, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Surveillance Summaries CONTENTS Introduction ............................................................................................................2 Methods ....................................................................................................................3 Results .......................................................................................................................6 Discussion ............................................................................................................. 21 References ............................................................................................................. 26 The MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30329-4027. Suggested citation: [Author names; first three, then et al., if more than six.] [Title]. MMWR Surveill Summ 2018;67(No. SS-#):[inclusive page numbers]. Centers for Disease Control and Prevention Robert R. Redfield, MD, Director Anne Schuchat, MD, Principal Deputy Director Leslie Dauphin, PhD, Acting Associate Director for Science Joanne Cono, MD, ScM, Director, Office of Science Quality Chesley L. Richards, MD, MPH, Deputy Director for Public
    [Show full text]
  • COARTEM  Coadministration of Strong Inducers of CYP3A4 Such As Rifampin, Carbamazepine, Tablets Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION (4) These highlights do not include all the information needed to use COARTEM Coadministration of strong inducers of CYP3A4 such as rifampin, carbamazepine, Tablets safely and effectively. See full prescribing information for phenytoin, and St. John’s wort with Coartem Tablets. (4, 7.1, 12.3) COARTEM Tablets. ® -----------------------------WARNINGS AND PRECAUTIONS---------------------- COARTEM (artemether and lumefantrine) tablets, for oral use Avoid use in patients with known QT prolongation, those with hypokalemia or Initial U.S. Approval: 2009 hypomagnesemia, and those taking other drugs that prolong the QT interval. (5.1, ------------------------------INDICATIONS AND USAGE----------------------------- 12.6) Coartem Tablets are a combination of artemether and lumefantrine, both Halofantrine and Coartem Tablets should not be administered within one month of antimalarials, indicated for treatment of acute, uncomplicated malaria each other due to potential additive effects on the QT interval. (5.1, 5.2, 12.3) infections due to Plasmodium falciparum (P. falciparum) in patients 2 months Antimalarials should not be given concomitantly, unless there is no other treatment of age and older with a bodyweight of 5 kg and above. (1) option, due to limited safety data. (5.2) Coartem Tablets have been shown to be effective in geographical regions where QT prolonging drugs, including quinine and quinidine, should be used cautiously resistance to chloroquine has been reported. (1) following Coartem Tablets. (5.1, 5.2, 7.7, 12.3) Substrates, inhibitors, or inducers of CYP3A4, including antiretroviral Limitations of Use: (1) medications, should be used cautiously with Coartem Tablets, due to a potential Coartem Tablets are not approved for patients with severe or complicated P.
    [Show full text]
  • Standby Emergency Treatment for Malaria Patient Information Leaflet
    Standby Emergency Treatment for Malaria Patient Information Leaflet Standby emergency treatment for malaria is recommended for those taking chemoprophylaxis and visiting remote areas where access to medical treatment may not be possible within 24 hours. It is intended for those travellers who believe that they may have malaria and is not a replacement for antimalarial chemoprophylaxis. The following written information should be followed. Incubation Period of Malaria The minimum period between being bitten by an infected mosquito and developing symptoms of malaria is 8 days, so a febrile illness starting within the first week of your arrival in a malarious area is not likely to be due to malaria. Symptoms and Signs of Malaria Malaria usually begins with a fever. You may then feel cold, shivery, shaky and very sweaty. Headache, feeling sick and vomiting are common with malaria and you are also likely to experience aching muscles. Some people develop jaundice (yellowness of the whites of the eyes and the skin). It is not necessary for all these symptoms to be present before suspecting malaria as fever alone may be present at first. When to Take Standby Emergency Treatment for Malaria If you develop a fever of 38°C [100°F] or more, more than one week after being in a malarious area, please seek medical attention straight away. If you will not be able to get medical attention within 24 hours of your fever starting, start your standby medication and set off to find and consult a doctor. How to Take Standby Emergency Treatment for Malaria First, take medication (usually paracetamol) to lower your fever.
    [Show full text]